What is NVS stock price target for 2026?

WallStSmart's 12-month price target for Novartis AG ADR is $131.02, representing 11.4% downside from the current price of $147.85.

What is NVS stock forecast?

Novartis AG ADR forecast includes bull, base, and bear case scenarios from 2026 through 2030. Revenue and EPS projections are derived from analyst consensus and conservative extrapolation with growth deceleration for outer years.

Is NVS undervalued based on price targets?

Our DCF intrinsic value for Novartis AG ADR is $109.60, against a current price of $147.85. The margin of safety is -52.47%.

NVS

Novartis AG ADR

NYSE: NVS · HEALTHCARE · DRUG MANUFACTURERS - GENERAL

$147.85

+3.44% today

Updated 2026-04-30

Market cap

$282.11B

P/E ratio

21.18

P/S ratio

4.99x

EPS (TTM)

$6.98

Dividend yield

3.21%

52W range

$102 – $165

Volume

2.1M

Market cap

$282.11B

P/E ratio

21.18

P/S ratio

4.99x

EPS (TTM)

$6.98

Dividend yield

3.21%

52W range

$102 – $165

Volume

2.1M

Novartis AG ADR (NVS) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current

$147.85

Consensus

$144.00

-2.60%

2030 Target

$145.47

-1.61%

DCF

$109.60

-52.47% MoS

Current price

$147.85

Analyst consensus

$144.00

-2.60%

2030 Target

$145.47

-1.61%

Intrinsic (DCF)

$109.60

-52.47% MoS

28 analysts:

2 Buy2 Hold1 Sell

Management guidance

No specific CEO revenue targets for 2026-2030 found in available data. Company focused on innovative medicines portfolio post-Sandoz spin-off with mid-single-digit revenue growth expectations. Recent acquisitions (Excellergy $2B, Synnovation $3B, Avidity $12B) signal strategic M&A to drive pipeline expansion and revenue growth.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range

Bull case (2030)

$232.75

$72.0B Rev × 6.4x P/S

Base case (2030)

$145.47

$72.0B Rev × 4x P/S

Bear case (2030)

$87.28

$72.0B Rev × 2.4x P/S

Financial forecast — research-backed

Metric	2023	2024	2025	2026 (E)	2027 (E)	2028 (E)	2029 (E)	2030 (E)
Revenue	$46.7B	$51.7B	$54.8B	$58.0B	$61.0B	$64.4B	$68.1B	$72.0B
Revenue growth	—	10.8%	6.0%	2.3%	5.3%	5.5%	5.7%	5.7%
EPS	$6.81	$7.81	$8.98	$8.97	$9.83	$10.45	$11.15	$11.90
P/S ratio	—	—	—	4.0x	4.0x	4.0x	4.0x	4.0x
Implied price	—	—	—	$116.38	$130.92	$130.92	$145.47	$145.47

Catalysts & risks

Growth catalysts

+ Itvisma (SMA gene therapy) EU approval expanding market access across age groups

+ Kisqali and Pluvicto momentum in oncology driving high-margin revenue growth

+ Recent pipeline acquisitions (Excellergy allergy, Synnovation breast cancer, Avidity heart disease) accelerating innovative medicines portfolio

+ Kesimpta immunology franchise expansion

+ Radioligand therapy manufacturing expansion in Texas supporting oncology growth

Key risks

- Patent cliffs on Entresto and Cosentyx creating revenue headwinds

- Biosimilar competition intensifying on key molecules

- U.S. drug pricing reforms and healthcare policy changes impacting margins

- Integration risk from $12B+ recent acquisitions

- Analyst consensus shows mixed ratings (Hold majority) with only modest price upside

Methodology

Novartis AG ADR's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 28 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 27, 2026.